# Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy

> **NCT00216645** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 74 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00216645
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216645, "Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT00216645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*